MedTrace Logo

Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse

NCT00373503 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-02-05

No results posted yet for this study

Summary

The purpose of this study is to investigate the interaction between marijuana and two potential treatment medications: lofexidine and oral THC, with the direct goal of using this information to improve marijuana treatment outcome.

Conditions

  • Marijuana Dependence

Interventions

DRUG

Lofexidine

alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity

DRUG

dronabinol

cannabinoid agonist hypothesized to decrease MJ withdrawal

DRUG

Marijuana

marijuana intoxication, withdrawal and relapse assessed

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Margaret Haney, Ph.D. · New York State Psychiatric Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2007-06-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373503 on ClinicalTrials.gov